Grifols Procleix ArboPlex Assay Revolutionizes Arbovirus Screening: First 4-in-1 NAT to Receive CE Mark
BARCELONA, Spain - Grifols, a global leader in plasma-derived medicines and diagnostic solutions, has recently achieved a significant milestone in the field of arbovirus screening. The company announced that its groundbreaking Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation (IVDR). This accomplishment not only positions Grifols as the first to develop an automated nucleic acid test (NAT) specifically validated for screening blood donors, but it also represents the first ever NAT to detect four major arboviruses: chikungunya, dengue, West Nile, and Zika.
Arboviruses, or arthropod-borne viruses, are primarily transmitted by insects such as mosquitoes and ticks. These viruses pose a significant global health threat, causing diseases that range in severity from mild flu-like symptoms to severe neurological complications and even death. The rapid and accurate detection of arboviruses is crucial for both the protection of blood transfusion recipients and the prevention of potential outbreaks.
The Procleix ArboPlex Assay comprises a state-of-the-art automated system that efficiently screens blood samples for the presence of arboviruses using nucleic acid amplification technology. By integrating the detection of multiple arboviruses into a single test, this innovative assay provides a comprehensive solution for ensuring the safety of blood supplies.
Obtaining the CE mark for the Procleix ArboPlex Assay signifies compliance with the rigorous quality and safety standards set forth by the European Union. This certification has far-reaching implications for Grifols, as it enables the company to market and distribute their groundbreaking assay to healthcare providers and blood banks across Europe.
The impact of this achievement on Grifols’ reputation and market position is significant. As one of the world’s leading producers of plasma-derived medicines and diagnostic solutions, Grifols continues to demonstrate its commitment to delivering cutting-edge technologies to improve public health. Through the Procleix ArboPlex Assay, the company has strengthened its position as an innovative industry leader, contributing to the advancement of arbovirus screening and enhancing the safety of blood transfusions.
In conclusion, Grifols’ Procleix ArboPlex Assay has emerged as a game-changer in arbovirus screening, receiving the first-ever CE mark for a 4-in-1 NAT. By addressing the major arboviruses that threaten public health, this innovative assay adds a new level of safety to blood transfusions. Grifols’ achievement not only benefits the company but also the millions of individuals who rely on blood transfusions worldwide.
Comments